05/05/22 4:01 PMNasdaq : AXNX earningsAxonics® Reports First Quarter 2022 Financial ResultsAxonics, Inc., a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported financial results for the three months ended March 31, 2022. “We are pleased with this quarter’ s revenue result considering the significant impact the Omicron surge had on elective...RHEA-AIneutral
04/26/22 6:00 AMNasdaq : AXNX conferencesAxonics® to Participate in BofA Securities 2022 Healthcare ConferenceAxonics, Inc., a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, will participate in the BofA Securities 2022 Healthcare Conference on May 10, 2022. Axonics is scheduled to present at 12:20 p.m. Eastern Time. About Axonics Based in Irvine, Calif., Axonics is a global...RHEA-AIneutral
04/19/22 6:00 AMNasdaq : AXNX Axonics® Announces Comprehensive Launch of the Axonics F15™ Recharge-Free Sacral Neuromodulation SystemAxonics, Inc., a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced the comprehensive launch of the Axonics F15 across the United States. Clinical outcomes with the Axonics rechargeable SNM system have exceeded our expectations and we anticipate...RHEA-AIneutral
04/14/22 4:01 PMNasdaq : AXNX conferencesearningsAxonics® to Report First Quarter 2022 Financial Results on May 5Axonics, Inc., a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, will report first quarter 2022 financial results after the market closes on Thursday, May 5, 2022. In conjunction with the release, Axonics will host a conference call at 4:30 p.m. Eastern Time.RHEA-AIneutral
04/04/22 6:00 AMNasdaq : AXNX Axonics® Launches Direct to Consumer Television Advertising CampaignAxonics, Inc., a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced the launch of its direct to consumer television advertising campaign. The advertisements feature women with urinary incontinence that have been treated with Axonics sacral...RHEA-AIneutral
03/07/22 4:01 PMNasdaq : AXNX fda approvalAxonics® Receives FDA Approval for Recharge-Free Sacral Neuromodulation SystemAxonics, Inc., a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that the U.S. Food and Drug Administration has approved its newly developed, long-lived, recharge-free sacral neuromodulation implantable neurostimulator. “Axonics is keenly...RHEA-AIneutral
02/24/22 4:01 PMNasdaq : AXNX earningsAxonics® Reports Fourth Quarter and Fiscal Year 2021 Financial ResultsAxonics, Inc., a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported financial results for the three months and fiscal year ended December 31, 2021. “We are proud of our fourth quarter and fiscal year 2021 results considering the disruption Covid-19 has...RHEA-AIneutral
02/03/22 6:00 AMNasdaq : AXNX conferencesearningsAxonics® to Report Fourth Quarter and Fiscal Year 2021 Financial Results on February 24Axonics, Inc., a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, will report fourth quarter and fiscal year 2021 financial results after the market closes on Thursday, February 24, 2022. In conjunction with the release, Axonics will host a conference call at...RHEA-AIneutral
02/01/22 6:00 AMNasdaq : AXNX conferencesAxonics® to Participate in SVB Leerink Virtual Healthcare ConferenceAxonics, Inc., a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, is scheduled to participate in the SVB Leerink Virtual Healthcare Conference on February 17, 2022. Axonics is scheduled to present at 12:00 p.m. Eastern Time. Based in Irvine, Calif., Axonics is a global...RHEA-AIneutral
01/25/22 6:00 AMNasdaq : AXNX New Study Finds More Than 60% of Adult Women in the U.S. Experience Urinary IncontinenceAxonics, Inc., a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today highlighted the publication of a new study that provides updated estimates of urinary incontinence prevalence in the U.S.. The overall prevalence of UI in adult U.S. women 20 years and older is...RHEA-AIneutral